Cefoxitin

Cefoxitin is a potent second-generation cephalosporin (cephamycin) antibiotic used to treat a wide range of bacterial infections, including those in the abdomen, pelvis, and skin. It is notable for its activity against anaerobic bacteria.

The dosage of Cefoxitin is determined by the severity of the infection, the susceptibility of the causative organism, and the patient's overall health. According to standard clinical guidelines:

• General Infections: For mild to moderate infections, the typical dose is 1 gram every 6 to 8 hours (3 to 4 grams per day).
• Severe Infections: For life-threatening or highly resistant infections, the dose may be increased to 2 grams every 4 hours or 3 grams every 6 hours (up to 12 grams per day).
• Surgical Prophylaxis: To prevent infection during surgery, a 2-gram dose is usually given intravenously 30 to 60 minutes before the initial incision. For prolonged procedures, additional doses may be given during surgery. Prophylactic use is generally discontinued within 24 hours after surgery.
• Uncomplicated Gonorrhea: A single 2-gram IM dose is sometimes used, often accompanied by 1 gram of oral probenecid to delay excretion and prolong the drug's effect.

Cefoxitin is approved for use in pediatric patients, including neonates. However, the dosage must be carefully calculated based on the child's body weight:

• Infants and Children (3 months and older): The usual dose is 80 to 160 mg per kilogram (mg/kg) of body weight per day, divided into 4 to 6 equal doses. The total daily dose should not exceed 12 grams.
• Neonates (under 3 months): The recommended dose is 60 to 100 mg/kg/day, divided into 3 or 4 equal doses. Safety and efficacy in infants under 3 months have not been as extensively studied as in older children, so healthcare providers exercise caution in this age group.

Renal Impairment

Since Cefoxitin is primarily excreted by the kidneys, patients with reduced kidney function (renal insufficiency) require dose adjustments to prevent drug accumulation and toxicity. Adjustments are based on the Creatinine Clearance (CrCl) rate:

• CrCl 30-50 mL/min: 1-2 grams every 8-12 hours.
• CrCl 10-29 mL/min: 1-2 grams every 12-24 hours.
• CrCl 5-9 mL/min: 0.5-1 gram every 12-24 hours.
• CrCl <5 mL/min: 0.5-1 gram every 24-48 hours.
• Hemodialysis: A supplemental dose may be required after each dialysis session because the procedure removes Cefoxitin from the blood.

Hepatic Impairment

No specific dosage adjustment is typically required for patients with liver disease, as Cefoxitin is not significantly metabolized by the liver.

Elderly Patients

Older adults are more likely to have decreased renal function. Healthcare providers usually monitor kidney function closely and adjust the dose accordingly. The "start low and go slow" approach is often favored in the geriatric population.

Cefoxitin is administered by healthcare professionals in a clinical setting (hospital or infusion center).

• Intravenous (IV): The drug is injected into a large vein. It can be given as a slow injection over 3 to 5 minutes or as an intermittent infusion over 30 to 60 minutes.
• Intramuscular (IM): The drug is injected deep into a large muscle mass (such as the gluteus maximus). This route may be painful, and the powder is often reconstituted with 0.5% or 1% lidocaine (a local anesthetic) to reduce discomfort.
• Storage: Unopened vials should be stored at room temperature (20°C to 25°C). Once reconstituted, the solution's stability varies depending on the diluent used, often remaining stable for 24 hours at room temperature or 48-96 hours if refrigerated.

In a hospital setting, it is unlikely that a dose will be missed. However, if you are receiving Cefoxitin at home through an outpatient infusion service and miss a dose, contact your healthcare provider or home health nurse immediately. Do not double the next dose to catch up.

Symptoms of Cefoxitin overdose may include neuromuscular hyperexcitability or seizures, especially in patients with impaired kidney function who receive high doses. If an overdose is suspected, emergency medical treatment is required. Treatment is supportive, and Cefoxitin can be removed from the bloodstream through hemodialysis.

> Important: Follow your healthcare provider's dosing instructions exactly. Completing the full course of antibiotics is essential to ensure the infection is fully cleared and to prevent the development of antibiotic resistance.

Cefoxitin is generally well-tolerated, but like all antibiotics, it can cause side effects. The most common reactions occur at the site of administration:

• Local Reactions: Pain, tenderness, and hardness (induration) at the site of an intramuscular injection are very common.
• Thrombophlebitis: When given intravenously, Cefoxitin can cause inflammation of the vein (thrombophlebitis), which may feel like a warm, painful, or red streak along the vein.
• Gastrointestinal Issues: Diarrhea is the most common systemic side effect. It is usually mild and resolves after the medication is stopped.

These side effects may affect a smaller percentage of patients:

Before starting Cefoxitin, it is critical to inform your healthcare provider of your complete medical history, particularly any history of allergies to antibiotics. Cefoxitin should only be used to treat infections that are proven or strongly suspected to be caused by susceptible bacteria to prevent the development of drug-resistant bacteria.

No FDA black box warnings for Cefoxitin. While Cefoxitin is a potent medication, it does not currently meet the FDA criteria for a boxed warning, which is reserved for drugs with a high risk of serious or life-threatening adverse effects.

• Allergic Reactions / Anaphylaxis Risk: There is a significant risk of cross-sensitivity between cephalosporins and penicillins. Approximately 10% of patients with a history of penicillin allergy may also be allergic to Cefoxitin. If you have ever had a severe allergic reaction (anaphylaxis) to any beta-lactam antibiotic, Cefoxitin should be avoided or used with extreme caution under close medical supervision.

There are no absolute drug-drug contraindications where Cefoxitin must never be used; however, certain combinations are avoided due to extreme risk:

• Live Bacterial Vaccines (e.g., Typhoid Vaccine): Antibiotics like Cefoxitin can kill the live bacteria in the vaccine, rendering it ineffective. Vaccination should typically be delayed until at least 24 hours after the last dose of Cefoxitin.

• Aminoglycosides (e.g., Gentamicin, Amikacin): Concurrent use of cephalosporins and aminoglycosides may increase the risk of nephrotoxicity (kidney damage). If used together, kidney function must be monitored daily.
• Probenecid: Probenecid inhibits the renal tubular secretion of Cefoxitin. This leads to higher and more prolonged blood levels of the antibiotic. While sometimes used intentionally to increase efficacy, it can also increase the risk of side effects.

Cefoxitin is strictly contraindicated in the following circumstances:

• Known Hypersensitivity to Cefoxitin: Any patient who has had a previous documented allergic reaction to Cefoxitin Sodium must not receive the drug again.
• Severe Cephalosporin Allergy: Patients with a history of immediate and severe hypersensitivity reactions (e.g., anaphylaxis, angioedema, or SJS) to any drug in the cephalosporin class should not be given Cefoxitin. The structural similarities between these drugs mean a repeat reaction is highly likely and potentially fatal.

In these cases, the healthcare provider will perform a careful risk-benefit analysis:

• Penicillin Sensitivity: Because of the 10% cross-reactivity rate, Cefoxitin should be used with extreme caution in patients with a history of penicillin allergy. If the previous reaction was mild (e.g., a small rash), the drug may be used with monitoring. If the reaction was severe, it is generally avoided.

Cefoxitin is classified by the FDA as Pregnancy Category B. This means that animal reproduction studies have failed to demonstrate a risk to the fetus, but there are no adequate and well-controlled studies in pregnant women. Cefoxitin crosses the placenta and can be detected in fetal tissues. It is generally considered safe for use during pregnancy when clearly needed, such as for treating serious pelvic or abdominal infections. However, it should only be used if the potential benefit justifies the potential risk to the fetus. There is no evidence of teratogenicity (birth defects) associated with Cefoxitin.

Cefoxitin is excreted in human milk in low concentrations. While the amount of drug an infant would ingest is small, it can potentially lead to changes in the infant's gut flora (causing diarrhea or diaper rash) or lead to allergic sensitization. The American Academy of Pediatrics considers many cephalosporins compatible with breastfeeding. Healthcare providers usually recommend monitoring the nursing infant for these symptoms or, in some cases, temporarily pumping and discarding milk during the treatment course.

Cefoxitin is a bactericidal agent. Its primary molecular mechanism involves the inhibition of bacterial cell wall synthesis. Specifically, Cefoxitin binds to Penicillin-Binding Proteins (PBPs) located on the inner side of the bacterial cell membrane. These PBPs are enzymes (transpeptidases, carboxypeptidases, and endopeptidases) responsible for the assembly and cross-linking of the peptidoglycan layer. By inhibiting these enzymes, Cefoxitin prevents the formation of the cross-bridges that give the cell wall its strength. This results in an incomplete cell wall, leading to bacterial cell death through osmotic lysis. Cefoxitin is particularly effective because its 7-alpha-methoxy group creates steric hindrance, protecting the beta-lactam ring from being broken by many beta-lactamase enzymes.

The efficacy of Cefoxitin is primarily "time-dependent." This means that the most important factor for killing bacteria is the amount of time that the concentration of the drug in the blood remains above the Minimum Inhibitory Concentration (MIC) for the specific bacteria being treated. Unlike some other antibiotics, increasing the dose far above the MIC does not necessarily kill bacteria faster. Therefore, maintaining a consistent dosing schedule (e.g., every 6 hours) is more important than giving one very large dose.